Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis

Autor: Jeremy Chataway, Ferran Prados, Rogier A. Kievit, Richard Nicholas, Alan J. Thompson, John Greenwood, M. Jorge Cardoso, Jennifer M. Nicholas, Dennis Chan, Olga Ciccarelli, Carole H. Sudre, Sebastien Ourselin, Daniel C. Alexander, Frederik Barkhof, Arman Eshaghi

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 166(22), 11020-11027. National Academy of Sciences
O2, repositorio institucional de la UOC
Universitat Oberta de Catalunya (UOC)
Eshaghi, A, Kievit, R A, Prados, F, Sudre, C H, Nicholas, J, Cardoso, M J, Chan, D, Nicholas, R, Ourselin, S, Greenwood, J, Thompson, A J, Alexander, D C, Barkhof, F, Chataway, J & Ciccarelli, O 2019, ' Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis ', Proceedings of the National Academy of Sciences of the United States of America, vol. 166, no. 22, pp. 11020-11027 . https://doi.org/10.1073/pnas.1818978116
Proceedings of the National Academy of Sciences of the United States of America
Eshaghi, A, Kievit, R A, Prados, F, Sudre, C H, Nicholas, J, Cardoso, M J, Chan, D, Nicholas, R, Ourselin, S, Greenwood, J, Thompson, A J, Alexander, D C, Barkhof, F, Chataway, J & Ciccarelli, O 2019, ' Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis ', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 22, pp. 11020-11027 . https://doi.org/10.1073/pnas.1818978116

Significance Traditional analysis of clinical trials precludes a mechanistic understanding of drug actions. This is further compounded by the use of outcome measures in clinical trials not directly related to the mechanism of action of the medication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80323431bc54d3d534a9dd9ad7875fe2
https://doi.org/10.1073/pnas.1818978116